Information Provided By: 
Fly News Breaks for March 21, 2018
GBT
Mar 21, 2018 | 08:44 EDT
As previously reported, Morgan Stanley analyst Matthew Harrison downgraded Global Blood Therapeutics to Equal Weight from Overweight as part of a rebalancing after a "strong run" for small-to-mid cap biotech stocks. While Harrison said he continues to expect positive Part A data for GBT-440, he also believes consensus expectations already reflect positive data. Harrison, who has a $61 price target on Global Blood shares, kept his model unchanged.
News For GBT From the Last 2 Days
There are no results for your query GBT
